Literature DB >> 1325907

Molecular cloning of a new bombesin receptor subtype expressed in uterus during pregnancy.

V Gorbulev1, A Akhundova, H Büchner, F Fahrenholz.   

Abstract

The homology screening approach has been used to clone a new member of the guanine-nucleotide-binding-protein-coupled receptor superfamily from guinea pig uterus. The cloned cDNA encodes a 399-amino-acid protein and shows the highest amino acid similarity to members of the bombesin receptor family; 52% and 47% similarity to the gastrin-releasing-peptide (GRP) receptor and the neuromedin-B receptor, respectively. Binding experiments with the stably transfected LLC-PK1 cell line expressing the new receptor protein confirmed the bombesin-like nature of the cloned receptor. The relative order of ligand affinity, GRP = neuromedin C much greater than neuromedin B, suggests that the cloned cDNA represents the GRP subtype rather than the neuromedin-B subtype of bombesin receptors. Northern-blot analysis of mRNA species from several guinea-pig tissues showed that the mRNA for the new bombesin receptor subtype is expressed mainly in uteri of pregnant animals.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1325907     DOI: 10.1111/j.1432-1033.1992.tb17201.x

Source DB:  PubMed          Journal:  Eur J Biochem        ISSN: 0014-2956


  22 in total

1.  Selective reconstitution of gastrin-releasing peptide receptor with G alpha q.

Authors:  M R Hellmich; J F Battey; J K Northup
Journal:  Proc Natl Acad Sci U S A       Date:  1997-01-21       Impact factor: 11.205

Review 2.  Insights into bombesin receptors and ligands: Highlighting recent advances.

Authors:  Irene Ramos-Álvarez; Paola Moreno; Samuel A Mantey; Taichi Nakamura; Bernardo Nuche-Berenguer; Terry W Moody; David H Coy; Robert T Jensen
Journal:  Peptides       Date:  2015-05-11       Impact factor: 3.750

Review 3.  Bombesin receptor subtype 3 as a potential target for obesity and diabetes.

Authors:  Nieves González; Paola Moreno; Robert T Jensen
Journal:  Expert Opin Ther Targets       Date:  2015-06-12       Impact factor: 6.902

4.  Development and Characterization of a Novel, High-Affinity, Specific, Radiolabeled Ligand for BRS-3 Receptors.

Authors:  Irene Ramos-Alvarez; Lingaku Lee; Samuel A Mantey; Robert T Jensen
Journal:  J Pharmacol Exp Ther       Date:  2019-04-10       Impact factor: 4.030

5.  Pulmonary neuroendocrine cells and lung development: dim outlines emerge.

Authors:  Y E Miller
Journal:  J Clin Invest       Date:  1993-05       Impact factor: 14.808

6.  Cloning of a receptor for amphibian [Phe13]bombesin distinct from the receptor for gastrin-releasing peptide: identification of a fourth bombesin receptor subtype (BB4).

Authors:  S R Nagalla; B J Barry; K C Creswick; P Eden; J T Taylor; E R Spindel
Journal:  Proc Natl Acad Sci U S A       Date:  1995-06-20       Impact factor: 11.205

Review 7.  Immunomodulatory functions of the diffuse neuroendocrine system: implications for bronchopulmonary dysplasia.

Authors:  Mary E Sunday; Lin Shan; Meera Subramaniam
Journal:  Endocr Pathol       Date:  2004       Impact factor: 3.943

8.  Identification and functional characterization of hemorphins VV-H-7 and LVV-H-7 as low-affinity agonists for the orphan bombesin receptor subtype 3.

Authors:  Hans-Peter Lammerich; Annette Busmann; Christian Kutzleb; Martin Wendland; Petra Seiler; Claudia Berger; Peter Eickelmann; Markus Meyer; Wolf-Georg Forssmann; Erik Maronde
Journal:  Br J Pharmacol       Date:  2003-04       Impact factor: 8.739

9.  Gastrin releasing peptide receptor expression is decreased in patients with Crohn's disease but not in ulcerative colitis.

Authors:  W P ter Beek; E S M Muller; R A Van Hogezand; I Biemond; C B H W Lamers
Journal:  J Clin Pathol       Date:  2004-10       Impact factor: 3.411

10.  Molecular cloning and characterization of avian bombesin-like peptide receptors: new tools for investigating molecular basis for ligand selectivity.

Authors:  Maiko Iwabuchi; Kumiko Ui-Tei; Kazuhiko Yamada; Yoichi Matsuda; Yasushi Sakai; Kohichi Tanaka; Hiroko Ohki-Hamazaki
Journal:  Br J Pharmacol       Date:  2003-06       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.